Bottiglieri T, Godfrey P, Flynn T, Carney M W, Toone B K, Reynolds E H
Department of Neurology, King's College Hospital, London, United Kingdom.
J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1096-8. doi: 10.1136/jnnp.53.12.1096.
Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.
严重抑郁症患者脑脊液(CSF)中的S-腺苷甲硫氨酸(SAM)水平显著低于神经疾病对照组。静脉或口服SAM均会使脑脊液SAM显著升高,这表明SAM可穿越人体血脑屏障。这些观察结果为SAM的抗抑郁作用提供了合理依据,该作用已在多个国家得到证实。一组阿尔茨海默病痴呆患者的脑脊液SAM水平较低,这表明此类患者可能存在甲基化紊乱,因此需要进行SAM治疗试验。